SCHEMBL3465381

SCHEMBL3465381

C[C](CC(N)=O)c1ccnc(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.43
KDM1A O60341 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
PREP P48147 1/20 0.37
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3120987 0.83 AR (0.43) ARKDM1AHDAC1HDAC6CA12
SCHEMBL3124147 0.79 KDM1A (0.40) ARKDM1AHDAC1HDAC6CA12
SCHEMBL27827224 0.79 AR (0.40) ARKDM1AHDAC1HDAC6CA12
SCHEMBL3127472 0.78 PARP1 (0.48) KDM1AHDAC1HDAC6GABRPGABRD
SCHEMBL220172 0.78 KDM1A (0.44) ARKDM1AHDAC1HDAC6CA12
SCHEMBL30595888 0.78 KDM1A (0.44) ARKDM1AHDAC1HDAC6CA12
SCHEMBL31026889 0.78 PARP1 (0.48) KDM1AHDAC1HDAC6GABRPGABRD
SCHEMBL30315883 0.77 KDM4E (0.55) KDM1AHDAC1HDAC6CA12CA9
SCHEMBL2998198 0.77 KDM4E (0.55) KDM1AHDAC1HDAC6CA12CA9
Bromide SCHEMBL6203968 0.77 KDM1A (0.42) ARKDM1AHDAC1HDAC6CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 EP disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCR4 AR 1940/4885KDM1A 597/4885HDAC1 66/4885
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates CCR1, CCRL2, CCR4 AR 4299/4885KDM1A 3501/4885HDAC1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.